These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 19131130)

  • 21. Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: results from the SIMONE study.
    De Socio GV; Parruti G; Quirino T; Ricci E; Schillaci G; Adriani B; Marconi P; Franzetti M; Martinelli C; Vichi F; Penco G; Sfara C; Madeddu G; Bonfanti P;
    J Infect; 2008 Jul; 57(1):33-40. PubMed ID: 18436307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.
    Masiá M; Padilla S; Bernal E; Almenar MV; Molina J; Hernández I; Graells ML; Gutiérrez F
    Clin Ther; 2007 Jul; 29(7):1448-55. PubMed ID: 17825696
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First Italian consensus statement on diagnosis, prevention and treatment of cardiovascular complications in HIV-infected patients in the HAART era (2006).
    Carosi G; Quiros-Roldan E; Torti C; Antinori A; Bevilacqua M; Bonadonna RC; Bonfanti P; Castagna A; Cauda R; d'Arminio-Monforte A; Di Gregorio P; Di Perri G; Esposito R; Fatuzzo F; Gervasoni C; Giannattasio C; Guaraldi G; Lazzarin A; Lo Caputo S; Maggi P; Mazzotta F; Moroni M; Prestileo T; Ranieri R; Rizzardini G; Russo R; Galli M;
    Infection; 2007 Jun; 35(3):134-42. PubMed ID: 17565453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular risk and risk management in HIV-infected patients.
    Adeyemi O
    Top HIV Med; 2007; 15(5):159-62. PubMed ID: 18073451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy.
    Grover SA; Coupal L; Gilmore N; Mukherjee J
    Am J Cardiol; 2005 Mar; 95(5):586-91. PubMed ID: 15721096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV lipodystrophy and its metabolic consequences: implications for clinical practice.
    Wierzbicki AS; Purdon SD; Hardman TC; Kulasegaram R; Peters BS
    Curr Med Res Opin; 2008 Mar; 24(3):609-24. PubMed ID: 18208641
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virus.
    Beltrán LM; Rubio-Navarro A; Amaro-Villalobos JM; Egido J; García-Puig J; Moreno JA
    Vasc Health Risk Manag; 2015; 11():35-48. PubMed ID: 25609975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of HIV-1 infection on endocrine organs.
    Brown TT
    Best Pract Res Clin Endocrinol Metab; 2011 Jun; 25(3):403-13. PubMed ID: 21663835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular manifestations of HIV infection in children.
    Idris NS; Grobbee DE; Burgner D; Cheung MM; Kurniati N; Sastroasmoro S; Uiterwaal CS
    Eur J Prev Cardiol; 2015 Nov; 22(11):1452-61. PubMed ID: 25398702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Controversies regarding the pathogenesis of cardiovascular diseases in HIV patients].
    Barelli S; Angelillo-Scherrer A; Foguena AK; Periard D; Cavassini M
    Rev Med Suisse; 2011 Apr; 7(292):905-10. PubMed ID: 21674894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV-related mechanisms in atherosclerosis and cardiovascular diseases.
    Gibellini D; Borderi M; Clò A; Morini S; Miserocchi A; Bon I; Ponti C; Re MC
    J Cardiovasc Med (Hagerstown); 2013 Nov; 14(11):780-90. PubMed ID: 23656915
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating endothelial progenitor cells in HIV infection: a systematic review.
    Costiniuk CT; Hibbert BM; Simard T; Ghazawi FM; Angel JB; O'Brien ER
    Trends Cardiovasc Med; 2013 Aug; 23(6):192-200. PubMed ID: 23395428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of iron in HIV infection and its related cardiovascular complications.
    Mascitelli L; Goldstein MR
    J Cardiovasc Med (Hagerstown); 2014 Dec; 15(12):883-4. PubMed ID: 25353975
    [No Abstract]   [Full Text] [Related]  

  • 34. HIV-related cardiovascular disease: closing the gap in mortality.
    Holloway CJ; Boccara F
    Curr Opin HIV AIDS; 2017 Nov; 12(6):509-512. PubMed ID: 28984701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV-1, reactive oxygen species, and vascular complications.
    Porter KM; Sutliff RL
    Free Radic Biol Med; 2012 Jul; 53(1):143-59. PubMed ID: 22564529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention strategies for cardiovascular disease in HIV-infected patients.
    Stein JH; Hadigan CM; Brown TT; Chadwick E; Feinberg J; Friis-Møller N; Ganesan A; Glesby MJ; Hardy D; Kaplan RC; Kim P; Lo J; Martinez E; Sosman JM;
    Circulation; 2008 Jul; 118(2):e54-60. PubMed ID: 18566315
    [No Abstract]   [Full Text] [Related]  

  • 37. Neural effects of inflammation, cardiovascular disease, and HIV: Parallel, perpendicular, or progressive?
    Nemeth CL; Bekhbat M; Neigh GN
    Neuroscience; 2015 Aug; 302():165-73. PubMed ID: 25239371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular and Endothelial Disease in HIV Infection.
    Cespedes MS; Aberg JA
    Curr Infect Dis Rep; 2005 Jul; 7(4):309-315. PubMed ID: 15963333
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Getting to the heart of the matter: the need for tailored cardiovascular prevention strategies in patients with HIV.
    Filip I
    AIDS; 2022 Apr; 36(5):N1-N3. PubMed ID: 35323156
    [No Abstract]   [Full Text] [Related]  

  • 40. HIV and Cardiovascular Disease - An Ounce of Prevention.
    Freiberg MS
    N Engl J Med; 2023 Aug; 389(8):760-761. PubMed ID: 37486752
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.